Minetta C. Liu

TL;DR: A literature search and prospectively defined study selection sought systematic reviews, meta-analyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014 to provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early stage invasive breast cancer as mentioned in this paper.

TL;DR: Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.

TL;DR: Pembrolizumab monotherapy had a manageable safety profile and showed durable antitumor activity as first-line therapy for patients with PD-L1-positive mTNBC.

TL;DR: When added to standard neoadjuvant chemotherapy, pembrolizumab more than doubled the estimated pCR rates for both HR-positive/ERBB2-negative and triple-negative breast cancer, indicating that checkpoint blockade in women with early-stage, high-risk, ER BB2- negative breast cancer is highly likely to succeed in a phase 3 trial.

TL;DR: The first evidence of a strong correlation between CTC results and radiographic disease progression in patients receiving chemotherapy or endocrine therapy for MBC is provided and support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC.